The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 23, 2016
Filed:
Apr. 05, 2011
Robert K. Prud'homme, Lawrenceville, NJ (US);
Patrick J. Sinko, Annandale, NJ (US);
Howard A. Stone, Princeton, NJ (US);
Nathalie M. Pinkerton, Ottawa Hills, OH (US);
Lei Shi, Shanghai, CN;
Jiandi Wan, Lawrenceville, NJ (US);
Sherif Ibrahim, Old Bridge, NJ (US);
Dayuan Gao, East Brunswick, NJ (US);
Robert K. Prud'homme, Lawrenceville, NJ (US);
Patrick J. Sinko, Annandale, NJ (US);
Howard A. Stone, Princeton, NJ (US);
Nathalie M. Pinkerton, Ottawa Hills, OH (US);
Lei Shi, Shanghai, CN;
Jiandi Wan, Lawrenceville, NJ (US);
Sherif Ibrahim, Old Bridge, NJ (US);
Dayuan Gao, East Brunswick, NJ (US);
Rutgers, The State University of New Jersey, New Brunswick, NJ (US);
The Trustees of Princeton University, Princeton, NJ (US);
Abstract
The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.